Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.
Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.
The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.
Key benefits
Report scope
Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 includes:
Available deals are listed by:
Analyzing actual contract agreements allows assessment of the following:
For more information about this report visit https://www.researchandmarkets.com/r/4rpu2x
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.